Researchers Reveal Racial Disparities in Access to Remdesivir for Patients With Cancer and COVID-19
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
Endocrine Cancer
Conflicts of Interest Continue to Plague Oncology Guidelines and Research
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Why Cancer Centers May Need to Rethink the Hard Sell to Patients
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
FDA: Unacceptable NDMA Levels Identified in Certain Metformin ER Products
Specifically, unacceptable levels of this potentially carcinogenic impurity have been identified in products manufactured by 5 different firms.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Retevmo Gets Accelerated Approval for RET-Driven Lung, Thyroid Cancers
The FDA has granted accelerated approval to Retevmo™ (selpercatinib; Lilly).
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Regular Medical Surveillance in World Trade Center Emergency Personnel May Explain Increased Rates of Thyroid Cancer
Higher incidence of thyroid cancer in World Trade Center-exposed emergency workers is likely due to greater detection of asymptomatic thyroid cancer.
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
-
Loading...
-
Loading...
Next post in General Oncology
